v3.25.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Income Statement [Abstract]    
Revenue $ 46,850,000 $ 64,179,000
Operating expenses:    
Cost of revenue 39,125,000 38,335,000
Selling, general and administrative 39,564,000 40,885,000
Research and development 4,888,000 5,032,000
Goodwill impairment 12,435,000 0
Restructuring 0 (1,212,000)
Total operating expenses 96,012,000 83,040,000
Loss from operations (49,162,000) (18,861,000)
Other income (expense):    
Interest expense (6,778,000) (10,864,000)
Interest income 3,225,000 7,210,000
Other income 24,000 106,000
Loss before income taxes (52,691,000) (22,409,000)
Income tax expense 162,000 271,000
Net loss (52,853,000) (22,680,000)
Net loss attributable to non-controlling interests (22,908,000) (10,602,000)
Net loss attributable to Maravai LifeSciences Holdings, Inc. $ (29,945,000) $ (12,078,000)
Net loss per Class A common share attributable to Maravai LifeSciences Holdings, Inc., basic (in usd per share) $ (0.21) $ (0.09)
Net loss per Class A common share attributable to Maravai LifeSciences Holdings, Inc., diluted (in usd per share) $ (0.21) $ (0.09)
Weighted average number of Class A common shares outstanding, basic (in shares) 143,425 132,333
Weighted average number of Class A common shares outstanding, diluted (in shares) 143,425 132,333

Source

HTML PDF
ZIP